NCT01225640View on ClinicalTrials.gov

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Tuberculosis
Interventions
DRUG

PNU-100480

600 mg twice daily (BID) for 14 days

DRUG

PNU-100480

1200 mg once daily (QD) for 14 days

DRUG

RHZE

Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)

Trial Locations (2)

7530

Pfizer Investigational Site, Bellville

7700

Pfizer Investigational Site, Cape Town

All Listed Sponsors
lead

Sequella, Inc.

INDUSTRY

NCT01225640 - PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay | Biotech Hunter | Biotech Hunter